228 related articles for article (PubMed ID: 32606705)
1. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
Mathews M; Gopal S; Singh A; Nuamah I; Pungor K; Tan W; Soares B; Kim E; Savitz AJ
Neuropsychiatr Dis Treat; 2020; 16():1533-1542. PubMed ID: 32606705
[TBL] [Abstract][Full Text] [Related]
2. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
4. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
[TBL] [Abstract][Full Text] [Related]
5. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
6. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
Basu A; Benson C; Alphs L
J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review.
Edinoff AN; Doppalapudi PK; Orellana C; Ochoa C; Patti S; Ghaffar Y; Cornett EM; Kaye AJ; Viswanath O; Urits I; Kaye AM; Kaye AD
Front Psychiatry; 2021; 12():699748. PubMed ID: 34621193
[TBL] [Abstract][Full Text] [Related]
8. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
[TBL] [Abstract][Full Text] [Related]
9. Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
Li G; Keenan A; Daskiran M; Mathews M; Nuamah I; Orman C; Joshi K; Singh A; Godet A; Pungor K; Gopal S
Patient Prefer Adherence; 2021; 15():2239-2248. PubMed ID: 34629867
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
Wallman P; Clark I; Taylor D
J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
[TBL] [Abstract][Full Text] [Related]
11. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
[TBL] [Abstract][Full Text] [Related]
14. Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
O'Donnell A; Rao S; Turkoz I; Gopal S; Kim E
Neuropsychiatr Dis Treat; 2021; 17():1-9. PubMed ID: 33442251
[TBL] [Abstract][Full Text] [Related]
15. Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.
Turkoz I; Daskiran M; Starr HL; Najarian D; Lopena O; Obando C; Keenan A; Benson C; Gopal S
Neuropsychiatr Dis Treat; 2022; 18():1927-1937. PubMed ID: 36065384
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
Li X; Ye C; Zhang W; Jia M; Wang G
CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
[TBL] [Abstract][Full Text] [Related]
17. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
20. Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.
El Khoury AC; Patel C; Mavros P; Huang A; Wang L; Bashyal R
Neuropsychiatr Dis Treat; 2021; 17():3159-3170. PubMed ID: 34703236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]